Download PDF
Thromb Haemost 1989; 62(02): 648-650
DOI: 10.1055/s-0038-1646876
Review Article
Schattauer GmbH Stuttgart

Biologicals, Standards and Heparin

Duncan P Thomas
The National Institute for Biological Standards and Control, Potters Bar, Herts., U.K.
› Author Affiliations
Further Information

Publication History

Received 17 January 1989

Accepted after revision 03 April 1989

Publication Date:
30 June 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Dale HH. Letter written in 1960 describing the first meeting on international standards in Geneva in 1925. NIBSC archives.
    Google Scholar
  • 2 Finney D. Statistical Method in Biological Assay. 3rd edition Charles Griffin; 1978
    Google Scholar
  • 3 Macintosh FC. The biological standardization of heparin. Bull Health Org, League of Nations 1943; 1944; 10: 144-154
    PubMedGoogle Scholar
  • 4 Thomas DP, Curtis AD, Barrowcliffe TW. A collaborative study designed to establish the 4th International Standard for heparin. Thromb Haemostas 1984; 52: 148-153
    PubMedGoogle Scholar
  • 5 Petitou M, Duchaussoy P, Lederman I, Choay J, Jacquinet JC, Sinay P, Torri G. Synthesis of heparin fragments: a methyl alpha-pentaside with high affinity for antithrombin III. Carbohyd Res 1987; 167: 67-75
    CrossrefPubMedGoogle Scholar
  • 6 Ofosu FA, Danishefsky I, Hirsh J. (eds) Heparin and related polysaccharides: Structure and activities. Ann NY Acad Sci 1989; 556
    PubMedGoogle Scholar
  • 7 Barrowcliffe TW, Curtis AD, Tomlinson TP, Hubbard AR, Johnson EA, Thomas DP. Standardization of low molecular weight heparins: a collaborative study. Thromb Haemostas 1985; 54: 675-679
    PubMedGoogle Scholar
  • 8 Barrowcliffe TW, Curtis AD, Johnson EA, Thomas DP. An international standard for low molecular weight heparin. Thromb Haemostas 1988; 60: 1-7
    PubMedGoogle Scholar
  • 9 Fareed J, Hoppensteadt D, Walenga JM, Huan X, Messmore HL. Validity of the newly established low molecular weight heparin standard in cross referencing low molecular weight heparins. Haemo stasis 1988; 18: 33-47
    PubMedGoogle Scholar
  • 10 Miles AA, Perry WL. Biological potency and its relation to therapeutic efficacy. Bull World Health Org 1953; 9: 1-14
    PubMedGoogle Scholar
  • 11 Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low molecular weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 1982; 284: 375-379
    CrossrefPubMedGoogle Scholar
  • 12 Roller M, Schoch U, Buchmann P, Largiadèr F, von Felten A, Frick PG. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized double-blind study versus unfractionated heparin. Thromb Haemostas 1986; 56: 243-246
    PubMedGoogle Scholar